Stopping immunomodulatory medications in MS: Frequency, reasons and consequences

W O Tobin; B G Weinshenker

doi:10.1016/j.msard.2015.07.004

Stopping immunomodulatory medications in MS: Frequency, reasons and consequences

Mult Scler Relat Disord. 2015 Sep;4(5):437-443. doi: 10.1016/j.msard.2015.07.004. Epub 2015 Jul 8.

Authors

W O Tobin¹, B G Weinshenker²

Affiliations

¹ Department of Neurology, College of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
² Department of Neurology, College of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address: weinb@mayo.edu.

PMID: 26346792
DOI: 10.1016/j.msard.2015.07.004

Abstract

Prolonged periods of disease quiescence during long term treatment of patients with clinically isolated syndrome and MS may prompt consideration of discontinuing disease-modifying therapy (DMT). We reviewed pertinent studies to identify the frequency and reasons for discontinuation of DMT.

Keywords: Disease activity; Multiple sclerosis; Treatment discontinuation.

Publication types

Review

MeSH terms

Decision Making
Humans
Immunologic Factors / economics
Immunologic Factors / therapeutic use*
Immunomodulation
Medication Adherence* / psychology
Medication Adherence* / statistics & numerical data
Multiple Sclerosis / drug therapy*
Multiple Sclerosis / epidemiology
Multiple Sclerosis / physiopathology
Multiple Sclerosis / psychology
Withholding Treatment* / statistics & numerical data

Substances

Immunologic Factors